Pharmacodynamic and Pharmacokinetic Study of PL-ASA

Phase 4 Completed 36 enrolled PLx Pharma

RandomizedCrossoverDouble-blindBasic science

Summary

A randomized, open-label, 2-way crossover pharmacodynamic and pharmacokinetic study of a novel pharmaceutical lipid-aspirin complex formulation (PL-ASA) at an 81 mg dose

Timeline

Start: 2021-04-28
Primary completion: 2021-09-15
Completion: 2021-09-15

Publications

Franchi F, Schneider DJ, Prats J, Fan W, Rollini F, Been L, Taatjes-Sommer HS, Bhatt DL, Deliargyris EN, Angiolillo DJ. Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study. J Thromb Thrombolysis. 2022 Oct;54(3):373-381. doi: 10.1007/s11239-022-02687-5. Epub 2022 Aug 29.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PL2200	Unknown	81 mg	—

Indications

No indication recorded.